secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nexalin Technology, Inc. (NXL)
CIK:        0001527352
Form:       8-K
Filed at:   2024-07-30T23:59:59+00:00
Accession:  0001829126-24-005111
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

SVP of Clinical, Quality, & Regulatory Affairs Michael Nketiah resigns effective Aug 16, 2024
--------------------------------------------------------------------------------

- Michael Nketiah resigned as SVP of Clinical, Quality, & Regulatory Affairs, effective August 16, 2024.
- Departure is to pursue another professional opportunity; no disagreement with the company.
- He will continue serving until the effective date.
- No successor has been named in the filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1527352/000182912624005111/0001829126-24-005111-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1527352/000182912624005111/nexalintec_8k.htm
  HTML page:      https://secwatch.observer/filing/0001829126-24-005111

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer